Bronstein, Gewirtz & Grossman LLC Urges Regeneron Pharmaceuticals, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

A class action lawsuit has been filed against Regeneron Pharmaceuticals alleging that the company made materially false and misleading statements regarding its Phase III Fianlimab-Libtayo study. The complaint claims the study's preliminary statistical assumptions were flawed, the treatment arm showed no meaningful clinical differentiation from standard therapies, and the study was unlikely to achieve statistical significance on its primary endpoint. Investors who purchased Regeneron securities between August 1, 2025 and May 15, 2026 are encouraged to join the case.